HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alberto Ocaña Selected Research

SAR 020106

11/2020Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alberto Ocaña Research Topics

Disease

74Neoplasms (Cancer)
05/2022 - 02/2006
54Breast Neoplasms (Breast Cancer)
05/2022 - 04/2005
9Triple Negative Breast Neoplasms
03/2022 - 09/2015
7Ovarian Neoplasms (Ovarian Cancer)
08/2020 - 06/2012
3Carcinogenesis
02/2021 - 01/2009
2Stomach Neoplasms (Stomach Cancer)
01/2022 - 01/2020
2Neoplasm Metastasis (Metastasis)
10/2021 - 01/2020
2Head and Neck Neoplasms (Head and Neck Cancer)
01/2020 - 05/2008
2Bone Fractures (Bone Fracture)
01/2018 - 09/2011
2Second Primary Neoplasms (Neoplasms, Second)
01/2018 - 09/2011
2Colorectal Neoplasms (Colorectal Cancer)
10/2015 - 09/2011
1COVID-19
01/2022
1Hypersensitivity (Allergy)
10/2021
1Sarcoma (Soft Tissue Sarcoma)
09/2021
1Kidney Neoplasms (Kidney Cancer)
08/2021
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021
1Hematologic Neoplasms (Hematological Malignancy)
01/2020
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2019
1Philadelphia Chromosome
12/2019

Drug/Important Bio-Agent (IBA)

16Phosphotransferases (Kinase)IBA
08/2021 - 04/2007
15Trastuzumab (Herceptin)FDA Link
10/2021 - 04/2005
13Proteins (Proteins, Gene)FDA Link
01/2022 - 02/2006
9Pharmaceutical PreparationsIBA
01/2022 - 02/2008
8Phenobarbital (Luminal)FDA Link
05/2022 - 02/2016
8Immunoconjugates (Immunoconjugate)IBA
03/2022 - 10/2015
7Biomarkers (Surrogate Marker)IBA
10/2021 - 06/2014
6Proteolysis Targeting ChimeraIBA
01/2022 - 08/2019
6Dasatinib (BMS 354825)FDA Link
01/2020 - 09/2010
6Protein Kinases (Protein Kinase)IBA
03/2017 - 02/2013
5AntibodiesIBA
04/2021 - 07/2016
5Hormones (Hormone)IBA
12/2020 - 02/2006
5Ado-Trastuzumab EmtansineIBA
01/2020 - 10/2015
5Tyrosine Kinase InhibitorsIBA
08/2019 - 04/2007
5Biological ProductsIBA
08/2019 - 02/2006
4snake venom protein C activatorIBA
05/2022 - 08/2019
4tyrosine receptor (receptor, tyrosine)IBA
08/2021 - 09/2011
4DNA (Deoxyribonucleic Acid)IBA
11/2020 - 07/2010
4NeuregulinsIBA
12/2017 - 07/2007
4Drug CombinationsIBA
02/2013 - 02/2008
3LigandsIBA
09/2021 - 01/2016
3Transcription Factors (Transcription Factor)IBA
03/2021 - 09/2017
3Lapatinib (GW572016)FDA Link
01/2020 - 04/2007
3human ERBB2 proteinIBA
12/2019 - 07/2007
3Tyrosine (L-Tyrosine)FDA Link
10/2015 - 09/2010
2Membrane Proteins (Integral Membrane Proteins)IBA
01/2022 - 07/2019
2AntigensIBA
09/2021 - 08/2020
2Peptides (Polypeptides)IBA
02/2021 - 06/2008
2UbiquitinIBA
02/2021 - 01/2018
2Checkpoint Kinase 1IBA
11/2020 - 11/2017
2amsonic acid (DAS)IBA
12/2019 - 08/2019
2Aromatase InhibitorsIBA
01/2018 - 09/2011
2ORALIT (ORS)IBA
01/2018 - 09/2011
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
10/2014 - 09/2010
2Zoledronic Acid (Zometa)FDA Link
04/2010 - 12/2007
2Mitogen-Activated Protein KinasesIBA
01/2009 - 04/2007
1Interleukin-10 (Interleukin 10)IBA
01/2022
1Ligases (Synthetase)IBA
01/2022
1Cytotoxins (Cytolysins)IBA
12/2021
1CymenesIBA
09/2021
1Ruthenium CompoundsIBA
09/2021
1AminesIBA
09/2021
1RutheniumIBA
09/2021
1Platinum Compounds (Compounds, Platinum)IBA
09/2021
1PlicamycinFDA Link
09/2021
1Anti-Bacterial Agents (Antibiotics)IBA
09/2021
1Therapeutic UsesIBA
09/2021
1Blocking AntibodiesIBA
08/2021
1PolyestersIBA
07/2021
1Poly(ADP-ribose) Polymerase InhibitorsIBA
04/2021
1EnzymesIBA
02/2021
1ProteomeIBA
02/2021
1Estrogen ReceptorsIBA
02/2021
1sotorasibIBA
01/2021
1Cyclin-Dependent Kinases (cdk Proteins)IBA
12/2020
1SAR 020106IBA
11/2020
1PlatinumIBA
11/2020
1olaparibIBA
01/2020
1Immune Checkpoint InhibitorsIBA
01/2020
1IntegrinsIBA
01/2020
1Chimeric Antigen ReceptorsIBA
01/2020
1neratinibIBA
01/2020
1ARV-825IBA
08/2019
1phthalic acid (phthalate)IBA
08/2019
1cyclohexeneIBA
08/2019
14-cymene (p-cymene)IBA
08/2019
1Carboplatin (JM8)FDA LinkGeneric
08/2019
1dichloro(4- cymene)(1,3,5- triaza- 7- phosphatricyclo(3.3.1.1)decane)ruthenium(II)IBA
08/2019
1Cisplatin (Platino)FDA LinkGeneric
08/2019
12-propylamine (isopropylamine)IBA
08/2019
1Receptor Tyrosine Kinase-like Orphan ReceptorsIBA
07/2019
1Small Interfering RNA (siRNA)IBA
12/2018
1(+)-JQ1 compoundIBA
12/2018
1pertuzumabIBA
08/2018

Therapy/Procedure

36Therapeutics
03/2022 - 02/2006
12Drug Therapy (Chemotherapy)
09/2021 - 02/2006
3Immunotherapy
08/2021 - 01/2020
2Neoadjuvant Therapy
02/2021 - 01/2021
2Adjuvant Chemotherapy
12/2018 - 01/2017
1Cell- and Tissue-Based Therapy (Cell Therapy)
01/2020
1Genomic Medicine
01/2020